Evergreen Quality Fund GP Ltd. Takes $7.14 Million Position in 4D Molecular Therapeutics, Inc. $FDMT

Evergreen Quality Fund GP Ltd. bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 951,474 shares of the company’s stock, valued at approximately $7,136,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Wexford Capital LP acquired a new stake in 4D Molecular Therapeutics in the third quarter worth about $41,000. Daiwa Securities Group Inc. grew its stake in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares during the last quarter. Martingale Asset Management L P grew its stake in 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the last quarter. Gabelli Funds LLC acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $90,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $39,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT opened at $9.42 on Thursday. The company has a 50 day moving average price of $9.44 and a 200-day moving average price of $9.14. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.68 and a 1-year high of $12.34. The firm has a market cap of $492.48 million, a price-to-earnings ratio of -3.67 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. On average, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on FDMT. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Royal Bank Of Canada lifted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.